Bicycle therapeutics announces phase i dose escalation results from ongoing phase i/ii study of bt8009

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced monotherapy phase i dose escalation results of the ongoing phase i/ii trial of bt8009, a novel btc™ targeting nectin-4.
BCYC Ratings Summary
BCYC Quant Ranking